<DOC>
	<DOCNO>NCT00650663</DOCNO>
	<brief_summary>The purpose study evaluate whether coadministration ezetimibe 10 mg/day simvastatin 20 mg/day 12 week result great reduction LDL-C , total cholesterol ( TC ) , triglyceride ( TG ) , non HDL-C , apolipoprotein B ( ApoB ) , great increase HDL-C , compare simvastatin 20 mg/day monotherapy 12 week African-American subject primary hypercholesterolemia . This study perform good define efficacy ezetimibe coadministered simvastatin population .</brief_summary>
	<brief_title>Ezetimibe Plus Simvastatin Versus Simvastatin Alone African-American Subjects With Primary Hypercholesterolemia ( P03377 )</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<criteria>Adult AfricanAmerican Black subject diagnosis primary hypercholesterolemia plasma LDLC &gt; =145 mg/dL &lt; =250 mg/dL , plasma TG &lt; =350 mg/dL Postmenopausal woman receive postmenopausal hormonal therapy raloxifene must maintain stable HRT raloxifene regimen least 6 week throughout study Female subject nonchildbearing potential Willingness give write consent , participate complete studyrelated procedure , ability follow stable NCEP Step I ( stricter ) diet regimen keep diet diary require . Clinical laboratory test ( CBC , blood chemistry , urinalysis ) within normal limit ( except note ) clinically acceptable . ALT ( SGPT ) AST ( SGOT ) concentration &lt; =2 time upper limit normal ( ULN ) creatine phosphokinase &lt; =2 time ULN . Pregnancy situation , condition , illness , opinion investigator , may interfere optimal participation study Secondary form hyperlipidemia underlie disease likely limit life span less one year Known hypersensitivity contraindication simvastatin ezetimibe Use investigational drug within 30 day study entry Concomitant illnesses : congestive heart failure NYHA Class III IV ; obstructive cardiomyopathy ; uncontrolled cardiac arrhythmia ; severe aortic stenosis ; MI , CABG angioplasty within 3 month study ; unstable severe peripheral artery disease ; unstable angina pectoris ; studylimiting disorder hematologic , digestive central nervous system include cerebrovascular disease degenerative disease ; uncontrolled newly diagnose diabetes mellitus ; uncontrolled endocrine metabolic disease know influence serum lipid lipoprotein ( clinically euthyroid subject stable replacement dos thyroid hormone eligible enrollment ) ; uncontrolled hypertension ; know impairment renal function ( plasma creatinine &gt; 2.0 mg/dL ) , dysproteinemia , nephrotic syndrome renal disease ( 24hour urinary protein 3+ 1 gram ) ; hepatobiliary hepatic disease ( AST ALT &gt; 2 time upper limit reference range ) ; HIV positive ; know coagulopathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>